Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 2Melanoma 2Peritoneal Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

tremelimumab 1poly(I).poly(c12,U) 1olaparib 1lentiviral minigene vaccine of COVID-19 coronavirus 1genexol-PM 1abagovomab 1Topotecan 1Paclitaxel 1Oxaliplatin 1MOC31PE immunotoxin 1LY-2157299 1Introns 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gefitinib 1Drug Therapy 1Doxorubicin 1Cytoreduction Surgical Procedures 1Cisplatin 1Celecoxib 1Capecitabine 1Bevacizumab 1AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Peritoneal Neoplasms × Introns × Clear all
NCT02151448 2020-07-20

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

University of Pittsburgh

Phase 1/2 Completed
64 enrolled 18 charts
Gynecologic

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡